Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Phase II Study of Capecitabine and Weekly Docetaxel Followed by Capecitabine Maintenance for Patients With Metastatic Breast Carcinoma

This study has been terminated.
(Terminated due to lack of accrual)
Sponsor:
Information provided by:
Oncology Specialties, Alabama
ClinicalTrials.gov Identifier:
NCT00225056
First received: September 21, 2005
Last updated: April 18, 2007
Last verified: April 2007
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: November 2006
  Estimated Primary Completion Date: No date given